Display options
Cite
Hathaway CA, Rice MS, Townsend MK, et al. Prolactin and Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1652-1659doi: 10.1158/1055-9965.EPI-21-0139.
Hathaway, C. A., Rice, M. S., Townsend, M. K., Hankinson, S. E., Arslan, A. A., Buring, J. E., Hallmans, G., Idahl, A., Kubzansky, L. D., Lee, I. M., Lundin, E. A., Sluss, P. M., Zeleniuch-Jacquotte, A., & Tworoger, S. S. (2021). Prolactin and Risk of Epithelial Ovarian Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(9), 1652-1659. https://doi.org/10.1158/1055-9965.EPI-21-0139
Hathaway, Cassandra A, et al. "Prolactin and Risk of Epithelial Ovarian Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,9 (2021): 1652-1659. doi: https://doi.org/10.1158/1055-9965.EPI-21-0139
Hathaway CA, Rice MS, Townsend MK, Hankinson SE, Arslan AA, Buring JE, Hallmans G, Idahl A, Kubzansky LD, Lee IM, Lundin EA, Sluss PM, Zeleniuch-Jacquotte A, Tworoger SS. Prolactin and Risk of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1652-1659. doi: 10.1158/1055-9965.EPI-21-0139. Epub 2021 Jul 08. PMID: 34244157; PMCID: PMC8419083.
Copy Download .nbib Format: NLM
Share it on

Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1652-1659. doi: 10.1158/1055-9965.EPI-21-0139. Epub 2021 Jul 08.

Prolactin and Risk of Epithelial Ovarian Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Cassandra A Hathaway, Megan S Rice, Mary K Townsend, Susan E Hankinson, Alan A Arslan, Julie E Buring, Göran Hallmans, Annika Idahl, Laura D Kubzansky, I-Min Lee, Eva A Lundin, Patrick M Sluss, Anne Zeleniuch-Jacquotte, Shelley S Tworoger

Affiliations

  1. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
  2. Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  3. Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts.
  4. Department of Obstetrics and Gynecology, New York University Langone Health, New York, New York.
  5. Department of Population Health, New York University Langone Health, New York, New York.
  6. NYU Perlmutter Comprehensive Cancer Center, New York, New York.
  7. Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  8. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  9. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  10. Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
  11. Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
  12. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  13. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida. [email protected].

PMID: 34244157 PMCID: PMC8419083 DOI: 10.1158/1055-9965.EPI-21-0139

Abstract

BACKGROUND: Prolactin is synthesized in the ovaries and may play a role in ovarian cancer etiology. One prior prospective study observed a suggestive positive association between prolactin levels and risk of ovarian cancer.

METHODS: We conducted a pooled case-control study of 703 cases and 864 matched controls nested within five prospective cohorts. We used unconditional logistic regression to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between prolactin and ovarian cancer risk. We examined heterogeneity by menopausal status at blood collection, body mass index (BMI), age, and histotype.

RESULTS: Among women with known menopausal status, we observed a positive trend in the association between prolactin and ovarian cancer risk (

CONCLUSIONS: We found a trend between higher prolactin levels and increased ovarian cancer risk, especially among women with a BMI ≥ 25 kg/m

IMPACT: This work supports a previous study linking higher prolactin with ovarian carcinogenesis in a high adiposity setting. Future work is needed to understand the mechanism underlying this association.

©2021 American Association for Cancer Research.

References

  1. Ther Clin Risk Manag. 2007 Oct;3(5):929-51 - PubMed
  2. Am J Epidemiol. 2008 Mar 15;167(6):653-66 - PubMed
  3. J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 - PubMed
  4. Cent Eur J Immunol. 2017;42(2):150-155 - PubMed
  5. Cancer Causes Control. 2013 Apr;24(4):741-8 - PubMed
  6. Cancer Lett. 2006 Nov 18;243(2):160-9 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649-54 - PubMed
  8. Cancer Res. 2009 Jun 15;69(12):5226-33 - PubMed
  9. Cancer Lett. 2011 Nov 1;310(1):101-8 - PubMed
  10. Cancer Res. 2006 Feb 15;66(4):2476-82 - PubMed
  11. Ann Oncol. 2014 Jul;25(7):1422-1428 - PubMed
  12. Cancer Causes Control. 2003 Sep;14(7):599-607 - PubMed
  13. Breast Cancer Res Treat. 2003 May;79(2):241-52 - PubMed
  14. Gynecol Oncol. 2011 Sep;122(3):560-6 - PubMed
  15. Proc Soc Exp Biol Med. 1997 Feb;214(2):161-6 - PubMed
  16. PLoS Med. 2018 Sep 4;15(9):e1002644 - PubMed
  17. J Clin Oncol. 2014 Oct 1;32(28):3111-7 - PubMed
  18. Int J Cancer. 2007 Apr 1;120(7):1536-41 - PubMed
  19. J Clin Oncol. 2007 Apr 20;25(12):1482-8 - PubMed
  20. Stat Med. 2016 Feb 28;35(5):782-800 - PubMed
  21. Physiol Rev. 2000 Oct;80(4):1523-631 - PubMed
  22. Cancers (Basel). 2018 Jul 30;10(8): - PubMed
  23. Breast Cancer Res Treat. 1991 May;18 Suppl 1:S23-6 - PubMed
  24. Obstet Gynecol. 2010 Nov;116(5):1088-95 - PubMed
  25. Cancer Lett. 2018 Oct 1;433:221-231 - PubMed
  26. JAMA. 2005 Jul 6;294(1):47-55 - PubMed
  27. J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 - PubMed
  28. JAMA. 2005 Jul 6;294(1):56-65 - PubMed
  29. Diabetologia. 2018 Dec;61(12):2549-2560 - PubMed
  30. Lipids. 2016 Feb;51(2):179-87 - PubMed
  31. N Engl J Med. 2005 Mar 31;352(13):1293-304 - PubMed
  32. Cancer Res. 2020 Mar 15;80(6):1357-1367 - PubMed
  33. J Clin Oncol. 2016 Aug 20;34(24):2888-98 - PubMed
  34. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2532-42 - PubMed
  35. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 - PubMed
  36. Scand J Public Health Suppl. 2003;61:18-24 - PubMed
  37. Cancer Res. 2013 Aug 1;73(15):4810-9 - PubMed
  38. J Clin Invest. 2011 Apr;121(4):1402-11 - PubMed
  39. FEBS Lett. 2003 Jun 5;544(1-3):171-5 - PubMed
  40. Trends Endocrinol Metab. 2006 Apr;17(3):110-6 - PubMed
  41. Autoimmun Rev. 2015 Mar;14(3):223-30 - PubMed
  42. Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 - PubMed

Publication Types

Grant support